Intermediatebiotechnology
Recombinant DNA Technology
Overview
Recombinant DNA technology joins DNA from different sources using restriction enzymes (molecular scissors cutting at palindromic sites) and DNA ligase, usually inserting genes into plasmid vectors in bacteria. Born in 1972-73 (Boyer-Cohen), it produced human insulin (1978), growth hormone, and clotting factors: the foundation of the biotechnology industry.
Learning objectives
- Explain restriction enzymes and sticky ends
- Outline the recombinant DNA workflow
- Give landmark products (insulin, etc.)
- Describe biosafety considerations
Molecular scissors
Restriction enzymes (EcoRI, BamHI...) cut at specific 4-8 bp palindromic sequences, leaving sticky ends (single-stranded overhangs) or blunt ends. Bacteria evolved them to shred phage DNA; Werner Arber, Hamilton Smith, and Daniel Nathans won the 1978 Nobel for their discovery and application.
EcoRI cuts G^AATTC: the same sequence read 5'->3' on both strands.
The cut-paste-express workflow
Cut vector and insert with the same enzyme(s) -> mix: complementary sticky ends anneal -> ligase seals phosphodiester bonds -> transform bacteria -> select (antibiotic) and screen (blue-white). Express: the bacterial machinery transcribes/translates the human gene.
The first recombinant plasmid (frog + bacterial DNA) launched genetic engineering and a patent battle.
Landmark products
Human insulin (Humulin, 1982: first recombinant drug), growth hormone, factor VIII, erythropoietin, hepatitis B vaccine (yeast-expressed surface antigen), Bt crops, and chymosin for cheese: recombinant DNA quietly rebuilt medicine, agriculture, and food.
Diabetics used pig/cow insulin: allergenic and scarce. Recombinant human insulin ended that era.
Safety and regulation
The 1975 Asilomar conference set containment principles still used (BSL levels, disabled host strains). Recombinant work is regulated (NIH Guidelines); environmental release (GM crops) faces separate scrutiny. The technology's safety record over 50 years is strong.
Scientists paused and self-regulated before proceeding: the model for responsible innovation.
Key points
- Restriction enzymes cut palindromic sites; sticky ends enable joining
- Cut -> ligate -> transform -> select -> express
- Products: insulin, growth hormone, factor VIII, HepB vaccine, Bt crops
- Asilomar (1975) set the biosafety framework
Common misconceptions
✓ Truth: It moves specific DNA sequences via vectors; the host stays the same species, expressing one new gene.
✓ Truth: They anneal transiently; DNA ligase must seal the backbone for a stable recombinant.
Practice questions
Q1. Restriction enzymes recognize
- Random DNA
- Specific palindromic sequences
- RNA only
- Proteins
Restriction enzymes recognize specific 4-8 bp palindromic sequences, such as EcoRI's GAATTC site.
Q2. In recombinant DNA workflow, DNA ligase
- Cuts DNA
- Seals nicks between annealed fragments
- Copies DNA
- Makes primers
Ligase forms phosphodiester bonds joining vector and insert.
Q3. The first recombinant therapeutic approved was
- Penicillin
- Human insulin (Humulin)
- Aspirin
- Morphine
FDA approval 1982: the biotech industry's founding product.
Click a question to reveal the answer and explanation.
Frequently asked questions
Why are palindromic sites useful?
Both strands read the same 5'->3', so one enzyme cuts both strands symmetrically, creating matching ends.
What made Humulin historic?
First FDA-approved recombinant drug (1982): proof that engineered bacteria could manufacture human medicine.
What is gene pharming?
Producing pharmaceuticals in transgenic animals/plants (e.g., antithrombin in goat milk).